abacavir sulfate / dolutegravir sodium / lamivudine

This medicine is authorised for use in the European Union.


Triumeq is a medicine for treating infection with human immunodeficiency virus (HIV), the virus that causes acquired immunodeficiency syndrome (AIDS). It is used in adults and adolescents over 12 years old who weigh at least 40 kg.

Triumeq contains three active substances: dolutegravir, abacavir and lamivudine.

This EPAR was last updated on 26/02/2021

Authorisation details

Product details
Agency product number
Active substance
  • dolutegravir sodium
  • lamivudine
  • abacavir (as sulfate)
International non-proprietary name (INN) or common name
abacavir sulfate / dolutegravir sodium / lamivudine
Therapeutic area (MeSH)
HIV Infections
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
ViiV Healthcare B.V.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Van Asch van Wijckstraat 55 H
3811 LP Amersfoort
The Netherlands

Product information

14/01/2021 Triumeq - EMEA/H/C/002754 - WS/1810


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antivirals for systemic use

Therapeutic indication

Triumeq is indicated for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age weighing at least 40 kg.

Before initiating treatment with abacavir-containing products, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. Abacavir should not be used in patients known to carry the HLA-B*5701 allele.

Assessment history

Related content

How useful was this page?

Add your rating
4 ratings